Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

to fund operations for the next two to three years.

Pipeline Update

GATTEX

Nycomed has confirmed to NPS its commitment to license GATTEX for development and commercialization outside of North America. Under the terms of the agreement announced in September 2007, Nycomed will now pay NPS the $25 million balance of the $35 million up-front payment due NPS for the rights to develop and market GATTEX outside North America. In October 2007, NPS announced top-line results of the Phase 3 study of GATTEX in patients with short bowel syndrome (SBS). The company has requested a meeting to discuss the next steps in the drug's regulatory approval process with the FDA this year. NPS believes GATTEX could generate U.S. sales of between $150 and $250 million in this indication.

NPS is also running pre-clinical studies of GATTEX in support of a pediatric IND in necrotizing enterocolitis. NEC affects 12,000 neonates annually in the U.S. and mortality approaches 50% in infants weighing less than fifteen-hundred grams. Additional preclinical studies in chemotherapy-induced gastrointestinal mucositis will be initiated very soon. Chemotherapy-induced GI mucositis affects over 500,000 cancer patients in the U.S. annually.

Cinacalcet

NPS recently announced that Kirin Pharma has received approval to market cinacalcet HCl in Japan. This regulatory event triggered a $2 million milestone payment to NPS.

PREOS

In September 2007, the FDA granted orphan drug status for PREOS as a treatment for hypoparathyroidism. The company is currently supporting a two-year study with PREOS in patients with hypoparathyroidism. The study was initiated by Dr. John Bilezikian at Columbia University and is now 96% enrolled.

The company believes that as a result of recent fundraising activities, sales of non-core assets and the GATTEX partnership with Nycomed, it now has the financial resources to fund the continued U.S. development of PREOS in a variety of ind
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...
(Date:12/16/2009)... company,s revenues increase 22% for fiscal 2009; on ... , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix Biosystems ... and biological technologies, today reported financial results for ... year ended September 30, 2009, Microbix reported revenues ... same period in 2008. For fourth-quarter 2009, the ...
(Date:12/16/2009)... Trial conducted pursuant to Special Protocol Assessment ... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna ... AEZ) (the "Company"), a global biopharmaceutical company ... announced the initiation, by its partner Keryx ... Phase 3 registration clinical trial for perifosine ...
(Date:12/16/2009)... Eppendorf has initiated an,import ban for Nanosphere, ... of European patent EP 1 179 180 ... quantification of a target compound". The import,ban ... respective products into any country of,the European ... any,violating products. , ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2
... security guards came to the DHS Science and Technology Directorates ... list was an emergency escape hood worthy of James Bond: ... pound, folding to the dimensions of a DVD case, and ... must be maintenance-free, filter nerve, blood, and blister agents, remove ...
... SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: ... Nasdaq staff,deficiency letter on April 17, 2008 indicating ... price for Pharmacyclics, common stock has closed,below the ... share for continued,inclusion on The Nasdaq Global Market ...
... $18.9 Million Net Revenues, $0.03 Net Loss Per Share, ... Inc. (Nasdaq: VNUS ), a leading provider of ... today announced its,financial results for the first quarter ended ... quarter of 2008 increased 21% to $18.9,million compared with ...
Other Biology Technology:Boys in the Hood 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:12/16/2009)... seasonal exposure to pesticides in rivers and basins ... salmon populations. In addition to the widespread deterioration ... to commonly used pesticides may further inhibit the ... "Major efforts are currently underway to restore Pacific ... populations," says David Baldwin of the National Oceanic ...
(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...
(Date:12/16/2009)... 2009 National Instruments (Nasdaq: ... and control, and DENSO Robotics, a leader ... technology, today announced their collaboration to integrate ... robotic arms. The collaboration increases productivity and ... manufacturing applications. In today,s trend toward high-mix, ...
Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 1Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 2Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 3iTech Medical Provides Update on MPR Clinical Development Plan 58632 1iTech Medical Provides Update on MPR Clinical Development Plan 58632 2iTech Medical Provides Update on MPR Clinical Development Plan 58632 3iTech Medical Provides Update on MPR Clinical Development Plan 58632 4Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 1Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 2Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 3
... during a long-distance race may do serious harm rather ... too much, according to a cardiologist at UT Southwestern ... drink too much water during a race could put ... by a loss in the body's sodium content that ...
... of scientists led by biophysicist Stuart Lindsay from ... created the first reproducible single molecule negative differential ... groundbreaking experimental technique that provides a “roadmap?for designing ... were presented Feb. 18 by Lindsay at the ...
... today the launch of the new GeneChip(R) Globin-Reduction ... PreAnalytiX -- a joint venture between QIAGEN N.V. ... (Becton, Dickinson and Company). The new kits optimize ... with Affymetrix GeneChip technology and improve gene expression ...
Other Biology News:Bush, Cheney and Rumsfeld are now species of slime-mold beetles -- but strictly in homage 2Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics 2Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics 3Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3